ArticlePloS one2026
Association between different metabolic obesity phenotypes and colorectal adenoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and metabolic abnormalities are independently and interactively associated with colorectal adenoma (CRA). This study aimed to investigate the association between different metabolic obesity phenotypes and CRA, and to assess whether this relationship is influenced by stratification based on age and sex. PATIENTS AND
methodsA total of 2042 subjects were enrolled in this study. The patients were classified into four metabolic obesity phenotypes based on their body mass index (BMI) and metabolic status, including metabolically healthy non-obesity (MHNO), metabolically unhealthy non-obesity (MUNO), metabolically healthy obesity (MHO), and metabolically unhealthy obesity (MUO). Multiple logistic regression analysis and further subgroup analysis based on sex and age were performed to evaluate the association between the metabolic obesity phenotypes and the occurrence of CRA.
resultsIn the overall population, CRA was detected at significantly higher rates in both the MUNO and MUO phenotypes compared to the MHNO and MHO phenotypes. After adjusting for confounders, in the overall population, the MUNO (OR = 1.353, 95% CI: 1.099-1.666, P < 0.05) and MUO (OR = 1.558, 95% CI: 1.111-2.187, P < 0.05) phenotypes were identified as risk factors for the development of CRA compared to the MHNO phenotype. Subgroup analysis based on sex revealed that in female subjects, the MUNO phenotype (OR 1.694; 95% CI 1.243-3.308, p < 0.01) exhibited significantly elevated risks of CRA compared to those in the MHNO phenotype, whereas the MHO phenotype showed no significant differences. Furthermore, in the male subjects, no statistically significant differences were observed among the four groups. Subgroup analysis based on age revealed that under 60 years with the MUNO (OR = 1.648, 95% CI: 1.252-2.169, P < 0.01) phenotype and over 60 years with MUO (OR = 2.301, 95% CI: 1.252-4.348, P < 0.01) phenotype, had significantly increased risks of CRA.
conclusionMetabolically unhealthy phenotypes are associated with a higher risk of CRA incidence. Clinical screening for CRA should focus on metabolically unhealthy subjects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.